• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Seagen Inc.

    12/14/23 8:42:58 AM ET
    $SGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGEN alert in real time by email
    S-8 POS 1 d593258ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on December 14, 2023

    Registration No. 333-273617

    Registration No. 333-240236

    Registration No. 333-232397

    Registration No. 333-226370

    Registration No. 333-212688

    Registration No. 333-204331

    Registration No. 333-197992

    Registration No. 333-188446

    Registration No. 333-176144

    Registration No. 333-168672

    Registration No. 333-148188

    Registration No. 333-56670

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-273617

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-240236

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-232397

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-226370

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-212688

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-204331

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-197992

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-188446

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-176144

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-168672

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-148188

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-56670

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SEAGEN INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   91-1874389

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    21823 30th Drive SE

    Bothell, Washington 98021

    (Address of Principal Executive Offices) (Zip Code)

    Amended and Restated 2007 Equity Incentive Plan

    Amended and Restated 2000 Employee Stock Purchase Plan

    2000 Directors’ Stock Option Plan, as Amended

    1998 Stock Option Plan

    (Full title of the plans)

    Margaret M. Madden, Esq.

    Vice President

    Seagen Inc.

    66 Hudson Boulevard East

    New York, New York 10001

    (Name and address of agent for service)

    (212) 733-2323

    (telephone number, including area code, of agent for service)

     

     

    Copies to:

    David K. Lam

    Zachary S. Podolsky

    Wachtell, Lipton, Rosen & Katz

    51 West 52nd Street

    New York, New York 10019

    (212) 403-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    These Post-Effective Amendments relate to the following Registration Statements on Form S-8 (each, a “Registration Statement” and collectively, the “Registration Statements”) previously filed by Seagen Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”):

     

      •  

    Registration Statement on Form S-8 (File No. 333-273617), originally filed with the SEC on August 2, 2023, registering 5,190,000 shares of the Company’s Common Stock, par value $0.001 per share (“Shares”), issuable in connection with the Company’s Amended and Restated 2007 Equity Incentive Plan (the “Equity Incentive Plan”).

     

      •  

    Registration Statement on Form S-8 (File No. 333-240236), originally filed with the SEC on July 31, 2020, registering 6,000,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-232397), originally filed with the SEC on June 27, 2019, registering 1,000,000 Shares, issuable in connection with the Company’s Amended and Restated 2000 Employee Stock Purchase Plan (the “ESPP”).

     

      •  

    Registration Statement on Form S-8 (File No. 333-226370), originally filed with the SEC on July 26, 2018, registering 6,000,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-212688), originally filed with the SEC on July 26, 2016, registering 6,000,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-204331), originally filed with the SEC on May 20, 2015, registering 1,000,000 Shares, issuable in connection with the ESPP.

     

      •  

    Registration Statement on Form S-8 (File No. 333-197992), originally filed with the SEC on August 8, 2014, registering 4,500,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-188446), originally filed with the SEC on May 8, 2013, registering 4,000,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-176144), originally filed with the SEC on August 8, 2011, registering 700,000 Shares, issuable in connection with the ESPP.

     

      •  

    Registration Statement on Form S-8 (File No. 333-168672), originally filed with the SEC on August 9, 2010, registering 7,500,000 Shares, issuable in connection with the Equity Incentive Plan.

     

      •  

    Registration Statement on Form S-8 (File No. 333-148188), originally filed with the SEC on December 19, 2007, registering (a) 5,000,000 Shares, issuable in connection with the Equity Incentive Plan and (b) 500,000 Shares, issuable in connection with the Company’s 2000 Directors’ Stock Option Plan, as amended (the “Directors’ Stock Option Plan”).

     

      •  

    Registration Statement on Form S-8 (File No. 333-56670), originally filed with the SEC on March 7, 2001, registering (a) 11,899,297 Shares, issuable in connection with the Company’s 1998 Stock Option Plan; (b) 3,000,000 Shares, issuable in connection with the 2000 Employee Stock Purchase Plan; and (c) 400,000 Shares, issuable in connection with the Directors’ Stock Option Plan.

    These Post-Effective Amendments are being filed in connection with the closing on December 14, 2023 of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of March 12, 2023 (the “Merger Agreement”), by and among Pfizer Inc., a Delaware corporation (“Parent”), Aris Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company. On December 14, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.


    As a result of the Merger, the Company has terminated all offerings of the Company’s securities pursuant to the Registration Statements. In accordance with undertakings made by the Company in each Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offerings, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statements that remain unsold and any plan interests that are unissued as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities and the effectiveness of each such Registration Statement is hereby terminated.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on December 14, 2023. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

    SEAGEN INC.
    By:  

    /s/ Margaret M. Madden

      Name:   Margaret M. Madden
      Title:   Vice President
    Get the next $SGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGEN

    DatePrice TargetRatingAnalyst
    2/16/2023$140.00 → $175.00In-line → Outperform
    Evercore ISI
    2/16/2023$155.00 → $175.00Outperform → Strong Buy
    Raymond James
    2/6/2023$162.00 → $141.00Outperform → Market Perform
    SVB Securities
    11/21/2022$135.00Hold
    Truist
    10/11/2022$177.00 → $178.00Market Perform → Outperform
    BMO Capital Markets
    6/29/2022$220.00Outperform
    Raymond James
    6/24/2022$169.00Market Perform
    BMO Capital Markets
    2/16/2022$201.00 → $142.00Market Outperform
    JMP Securities
    More analyst ratings

    $SGEN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Seagen Inc.

      15-12G - Seagen Inc. (0001060736) (Filer)

      12/26/23 6:12:25 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Seagen Inc.

      S-8 POS - Seagen Inc. (0001060736) (Filer)

      12/14/23 8:47:48 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Seagen Inc.

      S-8 POS - Seagen Inc. (0001060736) (Filer)

      12/14/23 8:46:25 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/18/23 6:46:48 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/15/23 6:55:41 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/15/23 6:46:58 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Seagen Inc. (Amendment)

      SC 13D/A - Seagen Inc. (0001060736) (Subject)

      12/18/23 5:25:33 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Seagen Inc. (Amendment)

      SC 13G/A - Seagen Inc. (0001060736) (Subject)

      6/9/23 3:48:51 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Seagen Inc. (Amendment)

      SC 13D/A - Seagen Inc. (0001060736) (Subject)

      5/3/23 4:15:52 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seagen upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Seagen from In-line to Outperform and set a new price target of $175.00 from $140.00 previously

      2/16/23 7:26:41 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seagen upgraded by Raymond James with a new price target

      Raymond James upgraded Seagen from Outperform to Strong Buy and set a new price target of $175.00 from $155.00 previously

      2/16/23 6:40:35 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seagen downgraded by SVB Securities with a new price target

      SVB Securities downgraded Seagen from Outperform to Market Perform and set a new price target of $141.00 from $162.00 previously

      2/6/23 7:35:55 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Pfizer Completes Acquisition of Seagen

      Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR) Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ:SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, fo

      12/14/23 7:39:00 AM ET
      $PFE
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Update: Annual Changes to the Nasdaq-100® Index

      NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i

      12/12/23 6:00:00 PM ET
      $NDAQ
      $PFE
      $SGEN
      $TTWO
      Investment Bankers/Brokers/Service
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGEN
    Financials

    Live finance-specific insights

    See more
    • Update: Annual Changes to the Nasdaq-100® Index

      NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i

      12/12/23 6:00:00 PM ET
      $NDAQ
      $PFE
      $SGEN
      $TTWO
      Investment Bankers/Brokers/Service
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

      Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance Pfizer Inc. (NYSE:PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ:SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete

      12/12/23 6:45:00 AM ET
      $PFE
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

      -Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line Metastatic Urothelial Cancer after EV-302 Trial Demonstrates Near Doubling of Median Overall Survival- -Proposed Pfizer Transaction On-Track and Anticipated to Close in Late-2023 or Early-2024, Subject to Closing Conditions, with Ongoing FTC Review and Recent EC Approval- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023. David Epstein, Chief Executive Officer of Seagen said, "Seagen continues to build momentum in 2

      11/1/23 8:00:00 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

      Seagen Inc. (NASDAQ:SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company's Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American Society of Clinical Oncology (ASCO) and chairs the Women Who Conquer Cancer committee. "We are pleased to welcome Sandra to our Board of Directors given her extensive research and clinical trial experience, especially in HER2-positiv

      11/10/22 7:05:00 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

      Felix Baker, Ph.D., Appointed Chair of the Board Board Begins Search for New CEO Roger Dansey, M.D., Chief Medical Officer, Remains Interim CEO Seagen Inc. (NASDAQ:SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen's Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found. The Board had previously announced that Dr. Siegall was on a leave of absence and that it had formed a committee of independent directors

      5/16/22 6:00:00 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care